Anthony, who acts in hit shows such as BMF and Power, as well as being a TV host and founding the ThreeSixty program, which offers 18 to 21-year-olds mentorships and reentry programs to help them ...

Johnson & Johnson's Tremfya showed significant skin clearance in adults with low BSA moderate plaque psoriasis in the ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

Plaque psoriasis, a chronic autoimmune disorder that causes thick, scaly, itchy patches—the eponymous plaques—to form on the skin, affects more than 7.5 million adults in the United States.

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

1 Data from the Phase 3b SPECTREM study, the first prospective, large-scale ... "People who have special site plaque psoriasis with lesions that cover a smaller total area of their body are ...

An 18-year-old woman presents with a 7-year history of moderate to severe chronic plaque psoriasis involving her scalp, trunk, bilateral upper and lower extremities, and nails. Her chief complaint ...

VTAMA ® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque ...

Johnson & Johnson announced that treatment with TREMFYA, or guselkumab, resulted in clear or almost clear skin in the majority of adults ...